A new mechanism for certain autoimmune conditions takes a big step forward with impressive pivotal data on Argenx’s efgartigimod.
170 commercial trials were suspended in March while new patient starts slumped 65% as the pandemic swept the globe. April could look even worse.
Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
The study marks victory against Soliris, but Apellis could still find the market hard to crack.
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.